The knowledge is missing that is essential for cost-effective roll-out of personalised treatment of insomnia. This project solves the bottleneck by creating a research platform for combined online behavioural change intervention and long-term monitoring of sleep, traits and health. A growing database will allow for optimised sleep interventions tailor to personalised needs, capacities, limitations and estimated benefits.
This project aims to unravel mechanisms underlying beneficial effects of a novel food supplement on cognitive performance. This may contribute to the prevention of cognitive impairment and ultimately dementia. Focus will be on adults with an emerging pre-mild cognitive impairment condition who will benefit most from evidence-based intervention and prevention strategies.
The aim is to improve vaccines by including viral innate immune antagonists that are co-expressed with the antigen to boost vaccine efficacy.
Ex-COVID-19 patients will undergo medical tests and biological samples will be analysed to increase the understanding of who is at risk for chronic disease. The influence of environmental factors and of a lifestyle intervention will be analysed, and lab research will contribute to better mechanistic insights providing leads for interventions.
The human pluripotent stem cell derived heart models will be used for a rapid evaluation of important COVID-19 therapies and develop SARS-COV-2 disease models to investigate how infection affects the heart. Impact beyond conventional approaches will be accelerated by providing data immediately relevant to clinicians, within months of the project start.
Addition of glycerol esters of short chain fatty acid (eSCFA) to pig feed has beneficial health effects and can thereby reduce the use of antibiotics in the farming industry. This project investigates which specific antimicrobial peptides are upregulated by eSCFA and determines how these peptides add to the health benefit.
Angiotensin-II is a protein that plays a role in the development of acute lung injury in patients suffering from COVID-19 infection. Valsartan is a well-known, cheap drug in cardiovascular medicine with little side effects that blocks Angiotensin-II. This project investigates whether valsartan can prevent acute lung injury in COVID-19 infection.
An intranasal vaccine will be developed against COVID-19 consisting of a safe Newcastle disease virus (NDV) vector that expresses the spike protein of SARS-CoV-2. The vaccine will be produced in FDA-approved Vero cells and the safety and efficacy will be tested in a pre-clinical animal model.
The UU-EMC-Harbour consortium will leverage their experience and expertise in coronaviruses, heavy-chain antibody platform technologies and establishment of relevant animal models. Using established technology platforms, they will isolate and characterise potent neutralising SBDs (in the form of nanobodies and human HCAbs) targeting the spike glycoprotein of SARS-CoV-2.
The world is not well prepared for newly emerging zoonotic viruses with epidemic/pandemic potential. Newly developed vaccines or therapeutic antibodies will come too late in outbreak situations. Therefore, the aim is to develop novel broad-spectrum intervention concepts and/or solutions, which can be applicable to combat current and potential future emerging viruses.